Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members.

Ann Oncol. 2009 Aug;20(8):1319-29. doi: 10.1093/annonc/mdp322. Epub 2009 Jun 17.

2.

Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members.

Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4.

3.

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference.

Ann Oncol. 2007 Jul;18(7):1133-44. Review. Erratum in: Ann Oncol. 2007 Nov;18(11):1917.

PMID:
17675394
4.

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ; Panel members.

Ann Oncol. 2011 Aug;22(8):1736-47. doi: 10.1093/annonc/mdr304. Epub 2011 Jun 27.

5.

Adjuvant chemotherapy in luminal breast cancers.

Lim E, Winer EP.

Breast. 2011 Oct;20 Suppl 3:S128-31. doi: 10.1016/S0960-9776(11)70309-5. Review.

PMID:
22015279
6.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members.

Ann Oncol. 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303. Epub 2013 Aug 4.

7.
8.

St. Gallen endocrine response classes predict recurrence rates over time.

Koornstra RH, Beelen KJ, Vincent AD, van der Noort V, van Diest PJ, Linn SC.

Breast. 2015 Dec;24(6):705-12. doi: 10.1016/j.breast.2015.08.009. Epub 2015 Oct 1.

9.

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.

Bauer K, Parise C, Caggiano V.

BMC Cancer. 2010 May 21;10:228. doi: 10.1186/1471-2407-10-228.

10.

[Strategies of breast cancer treatment based on determination of biological subtype].

Semiglazov VF.

Vopr Onkol. 2011;57(5):542-52. Russian. No abstract available.

PMID:
22238922
11.

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, Sartorius CA.

Breast Cancer Res Treat. 2012 Sep;135(2):415-32. doi: 10.1007/s10549-012-2164-8. Epub 2012 Jul 24.

12.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.

Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell'Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group.

Breast Cancer Res Treat. 2015 Nov;154(2):275-86. doi: 10.1007/s10549-015-3612-z. Epub 2015 Oct 22.

13.

Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer.

Horii R, Akiyama F, Ito Y, Iwase T.

Br J Cancer. 2007 Sep 3;97(5):654-8. Epub 2007 Aug 28.

14.

Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.

Wright JL, Reis IM, Zhao W, Panoff JE, Takita C, Sujoy V, Gomez CR, Jorda M, Franceschi D, Hurley J.

Breast. 2012 Jun;21(3):276-83. doi: 10.1016/j.breast.2011.11.003. Epub 2011 Dec 16.

PMID:
22178596
15.

HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.

Rydén L, Landberg G, Stål O, Nordenskjöld B, Fernö M, Bendahl PO.

Breast Cancer Res Treat. 2008 May;109(2):351-7. Epub 2007 Jul 18.

PMID:
17636399
16.

Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.

Ma CX, Bose R, Ellis MJ.

Adv Exp Med Biol. 2016;882:125-54. doi: 10.1007/978-3-319-22909-6_5. Review.

PMID:
26987533
17.

Selecting adjuvant endocrine therapy for breast cancer.

Eneman JD, Wood ME, Muss HB.

Oncology (Williston Park). 2004 Dec;18(14):1733-44, discussion 1744-5, 1748, 1751-4. Review.

18.

Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?

Forbes JF, Gradishar WJ, Ravdin PM.

Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S37-44; discussion S57-9. Review.

PMID:
12353822
19.

Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL).

Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, Ambrosone CB, Bovbjerg DH, Mandelblatt JS, Magai C, Tsai WY, Jacobson JS, Hershman DL.

Breast Cancer Res Treat. 2012 Jul;134(1):419-28. doi: 10.1007/s10549-012-2066-9. Epub 2012 Apr 22.

20.

[Adjuvant chemotherapy in primary carcinoma of the breast].

Harbeck N.

Zentralbl Gynakol. 2003 Sep;125(9):322-6. Review. German.

PMID:
14569511

Supplemental Content

Support Center